Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – Adicet has a case of déjà vu
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
EHA 2022 preview – some good news at last
Positive data result in positive share price movements – something of a novelty in the current market.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.